Information de reference pour ce titreAccession Number: | 00006374-200726020-00010.
|
Author: | Zhang, Y-W 1; Staal, B 1; Su, Y 1; Swiatek, P 2; Zhao, P 3; Cao, B 3; Resau, J 4; Sigler, R 5; Bronson, R 6; Vande Woude, G F 1
|
Institution: | (1)Laboratory of Molecular Oncology, Van Andel Research Institute, Grand Rapids, MI, USA; (2)Laboratory of Germline Modification, Van Andel Research Institute, Grand Rapids, MI, USA; (3)Laboratory of Antibody Technology, Van Andel Research Institute, Grand Rapids, MI, USA; (4)Laboratory of Analytical, Cellular, and Molecular Microscopy, Van Andel Research Institute, Grand Rapids, MI, USA; (5)Esperion Therapeutics, Division of Pfizer, Ann Arbor, MI, USA and (6)Department of Pathology, Harvard Medical School, Boston, MA, USA
|
Title: | Evidence that MIG-6 is a tumor-suppressor gene.[Article]
|
Source: | Oncogene. 26(2):269-276, January 11, 2007.
|
Abstract: | Mitogen-inducible gene 6 (MIG-6) is located in human chromosome 1p36, a locus frequently associated with human lung cancer. MIG-6 is a negative regulator of epidermal growth factor (EGF) signaling, and we show that MIG-6 - like EGF - is induced by hepatocyte growth factor/scatter factor (HGF/SF) in human lung cancer cell lines. Frequently, the receptors for both factors, EGFR and Met, are expressed in same lung cancer cell line, and MIG-6 is induced by both factors in a mitogen-activated protein kinase-dependent fashion. However, not all tumor lines express MIG-6 in response to either EGF or HGF/SF. In these cases, we find missense and nonsense mutations in the MIG-6 coding region, as well as evidence for MIG-6 transcriptional silencing. Moreover, germline disruption of Mig-6 in mice leads to the development of animals with epithelial hyperplasia, adenoma, and adenocarcinoma in organs like the lung, gallbladder, and bile duct. These data suggests that MIG-6 is a tumor-suppressor gene and is therefore a candidate gene for the frequent 1p36 genetic alterations found in lung cancer.
Copyright (C) 2007 Nature Publishing Group
|
Author Keywords: | MIG-6; mutation; lung carcinogenesis; signal transduction; EGF; HGF/SF.
|
References: | Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, Gruenfelder A et al. (2004). Cancer Res 64: 844-856.
Anastasi S, Fiorentino L, Fiorini M, Fraioli R, Sala G, Castellani L et al. (2003). Oncogene 22: 4221-4234.
Anastasi S, Sala G, Huiping C, Caprini E, Russo G, Iacovelli S et al. (2005). Oncogene 24: 4540-4548.
Benhar M, Engelberg D, Levitzki A. (2002). EMBO Rep 3: 420-425.
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. (2003). Nat Rev Mol Cell Biol 4: 915-925.
Davis RJ. (2000). Cell 103: 239-252.
Ferby I, Reschke M, Kudlacek O, Knyazev P, Pante G, Amann K et al. (2006). Nature Med 12: 568-573.
Fiorentino L, Pertica C, Fiorini M, Talora C, Crescenzi M, Castellani L et al. (2000). Mol Cell Biol 20: 7735-7750.
Fujii T, Dracheva T, Player A, Chacko S, Clifford R, Strausberg RL et al. (2002). Cancer Res 62: 3340-3346.
Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD. (2000). Cancer Res 60: 4894-4906.
Herzog CR, Devereux TR, Pittman B, You M. (2002). Cancer Res 62: 6424-6429.
Herzog CR, Wang Y, You M. (1995). Oncogene 11: 1811-1815.
Keeton AB, Messina JL. (2005). J Cell Biochem 94: 1190-1198.
Keeton AB, Xu J, Franklin JL, Messina JL. (2004). Biochim Biophys Acta 1679: 248-255.
Kohno T, Yokota J. (1999). Carcinogenesis 20: 1403-1410.
Koo HM, McWilliams MJ, Alvord WG, Vande Woude GF. (1999). Cancer Res 59: 6057-6062.
Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA et al. (2005). Cancer Res 65: 1479-1488.
Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD et al. (2003). Cancer Res 63: 6272-6281.
Mai M, Yokomizo A, Qian C, Yang P, Tindall DJ, Smith DI et al. (1998). Cancer Res 58: 2347-2349.
Makkinje A, Quinn DA, Chen A, Cadilla CL, Force T, Bonventre JV et al. (2000). J Biol Chem 275: 17838-17847.
Miettinen PJ, Berger JE, Meneses J, Phung Y, Pederson RA, Werb Z et al. (1995). Nature 376: 337-341.
Miettinen PJ, Warburton D, Bu D, Zhao JS, Berger JE, Minoo P et al. (1997). Dev Biol 186: 224-236.
Nomoto S, Haruki N, Kondo M, Konishi H, Takahashi T, Takahashi T et al. (1998). Cancer Res 58: 1380-1383.
Nomoto S, Haruki N, Tatematsu Y, Konishi H, Mitsudomi T, Takahashi T et al. (2000). Genes Chromosomes Cancer 28: 342-346.
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. (2004). Science 304: 1497-1500.
Pante G, Thompson J, Lamballe F, Iwata T, Ferby I, Barr FA et al. (2005). J Cell Biol 171: 337-348.
Ragnarsson G, Eiriksdottir G, Johannsdottir JT, Jonasson JG, Egilsson V, Ingvarsson S. (1999). Br J Cancer 79: 1468-1474
Sargent LM, Senft JR, Lowry DT, Jefferson AM, Tyson FL, Malkinson AM et al. (2002). Cancer Res 62: 1152-1157.
Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J et al. (2004). Nature 431: 525-526.
Thiagalingam S, Foy RL, Cheng KH, Lee HJ, Thiagalingam A, Ponte JF. (2002). Curr Opin Oncol 14: 65-72.
Tokuchi Y, Hashimoto T, Kobayashi M, Hayashi M, Nishida S, Imai K et al. (1999). Br J Cancer 80: 1623-1629.
Tsunoda T, Inokuchi J, Baba I, Okumura K, Naito S, Sasazuki T et al. (2002). Cancer Res 62: 5668-5671.
Virmani AK, Fong KM, Kodagoda D, McIntire D, Hung J, Tonk V et al. (1998). Genes Chromosomes Cancer 21: 308-319.
Wick M, Burger C, Funk M, Muller R. (1995). Exp Cell Res 219: 527-535.
Xu D, Makkinje A, Kyriakis JM. (2005a). J Biol Chem 280: 2924-2933.
Xu J, Keeton AB, Wu L, Franklin JL, Cao X, Messina JL. (2005b). Breast Cancer Res Treat 91: 207-215.
Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J et al. (2000). Nature 404: 99-103.
Zhang YW, Su Y, Lanning N, Swiatek PJ, Bronson RT, Sigler R et al. (2005). Proc Natl Acad Sci USA 102: 11740-11745.
Zhang YW, Su Y, Volpert OV, Vande Woude GF. (2003). Proc Natl Acad Sci USA 100: 12718-12723.
Zochbauer-Muller S, Gazdar AF, Minna JD. (2002). Annu Rev Physiol 64: 681-708.
|
Language: | English.
|
Document Type: | Original Article.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0950-9232
|
NLM Journal Code: | onc, 8711562
|
Annotation(s) | |
|
|